Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular Drug Access in Australia and New Zealand: New PBS and PHARMAC Listings, 2023-2025.

Heart, lung & circulation·2026
Same author

Redo-TAVR (TAV-in-TAV) Best Practices Part 1: Short-in-Short and Short-in-Tall - A Heart and Valve Collaboratory Document.

JACC. Cardiovascular interventions·2026
Same author

Redo-TAVR (TAV-in-TAV) Best Practices Part 2: Tall-in-Short and Tall-in-Tall - A Heart and Valve Collaboratory Document.

JACC. Cardiovascular interventions·2026
Same author

Correction: Reduced Retinal Microvascular Density, Improved Forepaw Reach, Comparative Microarray and Gene Set Enrichment Analysis with c-jun Targeting DNA Enzyme.

PloS one·2026
Same author

Preemptive cardioprotection with a small molecule in rodents that suppresses genes predictive of heart failure.

Science advances·2026
Same author

Health and Medical Research in Australia I: A Long-term Investment that Drives Innovation and Endogenous Growth.

Drug discovery today·2026
Same journal

Non-transferrin-bound iron uptake by cardiomyocytes.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Beyond the target: implications of Wnt pathway inhibitors on bone health.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Proteomic analysis reveals divergent inflammatory mechanisms of COVID-associated Guillain-Barré syndrome.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Integrative genetic and functional analysis of autosomal dominant hearing loss in 108 multigenerational families.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Preclinical evaluation of cysteine protease-inhibitor aloxistatin (E64d) for heart failure therapy.

Journal of molecular medicine (Berlin, Germany)·2026
Same journal

Zinc-binding protein metallothionein 3 protects vascular smooth muscle cells from ferroptosis via blocking lysosomal degradation of GPX4.

Journal of molecular medicine (Berlin, Germany)·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Recent developments in drug-eluting stents.

Yue Li1, Ravinay Bhindi, Levon M Khachigian

  • 1Centre for Vascular Research, University of New South Wales, Sydney, Australia.

Journal of Molecular Medicine (Berlin, Germany)
|February 1, 2011
PubMed
Summary
This summary is machine-generated.

Drug-eluting stents (DES) have improved percutaneous coronary intervention (PCI) for coronary artery disease (CAD). This review covers recent advancements in DES technology to address restenosis and stent thrombosis.

More Related Videos

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

Related Experiment Videos

Last Updated: Jun 4, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Percutaneous coronary intervention (PCI) is a key treatment for symptomatic coronary artery disease (CAD).
  • Evolution of PCI includes balloon angioplasty, bare-metal stents, and drug-eluting stents (DES).
  • Despite benefits, DES use is limited by restenosis and late stent thrombosis.

Purpose of the Study:

  • To review recent advancements in drug-eluting stent (DES) technology.
  • To highlight improvements aimed at overcoming limitations of current DES.
  • To discuss future directions in DES development for CAD management.

Main Methods:

  • Literature review of recent studies on drug-eluting stents.
  • Analysis of technological innovations in DES design and drug delivery.
  • Synthesis of data on clinical outcomes, restenosis rates, and stent thrombosis.

Main Results:

  • Recent DES developments focus on novel stent materials and advanced drug-eluting coatings.
  • Newer generation DES show reduced rates of restenosis and late stent thrombosis compared to earlier models.
  • Ongoing research targets enhanced biocompatibility and sustained drug elution.

Conclusions:

  • Continuous innovation in DES technology is crucial for improving PCI outcomes in CAD patients.
  • Future DES aim to further minimize adverse events like restenosis and thrombosis.
  • Advancements in DES offer promising therapeutic options for managing complex coronary artery disease.